Feasibility of online home spirometry in systemic sclerosis associated interstitial lung disease: a pilot study

被引:23
|
作者
Moor, Catharina C. [1 ]
van Leuven, Sander, I [2 ]
Wijsenbeek, Marlies S. [1 ]
Vonk, Madelon C. [2 ]
机构
[1] Erasmus MC, Dept Pulmonol, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands
[2] Radboud Univ Nijmegen, Dept Rheumatol, Med Ctr, Nijmegen, Netherlands
关键词
SSc; interstitial lung disease; home spirometry; eHealth; home monitoring; EULAR SCLERODERMA TRIALS; DOUBLE-BLIND;
D O I
10.1093/rheumatology/keaa607
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives. Frequent monitoring of forced vital capacity at home may be of added value in patients with SSc-associated interstitial lung disease (SSc-ILD) to monitor disease progression and guide treatment decisions. The aim of this study was to evaluate the feasibility and optimal frequency of online home spirometry using a home monitoring application in patients with SSc-ILD. Methods. This was a prospective, observational study in patients with SSc-ILD. Patients evaluated for 3 months the online home monitoring application ILD-online integrated with a Bluetooth-connected spirometer. Patients performed daily home spirometry for 6 weeks and weekly home spirometry for 6 weeks. In addition, patients completed an evaluation questionnaire after 3 months and online patient-reported outcomes at baseline and 3 months. Results. Ten consecutive patients participated. Mean adherence to home spirometry was 98.8% (S.D. 1.5). Home and hospital spirometry were highly correlated. The mean coefficient of variation was lower for weekly [2.45% (S.D. 1.19)] than daily [3.86% (S.D. 1.45)] forced vital capacity measurements (P = 0 .0 0 5) . All patients considered the home monitoring application and spirometer easy to use and no patients considered home spirometry burdensome. All patients would recommend home monitoring to other patients with SSc. Conclusions. Home spirometry using an online home monitoring application is feasible in patients with SSc-ILD, with high adherence and patient satisfaction. Larger long-term studies are needed to assess whether home spirometry can detect the progression of ILD in patients with SSc.
引用
收藏
页码:2467 / 2471
页数:5
相关论文
共 50 条
  • [21] Management of Systemic-Sclerosis-Associated Interstitial Lung Disease
    Silver, Katherine Culp
    Silver, Richard M.
    RHEUMATIC DISEASE CLINICS OF NORTH AMERICA, 2015, 41 (03) : 439 - +
  • [22] Ethnic Variations in Systemic Sclerosis Associated Interstitial Lung Disease
    Donio, Patrick
    Fidler, Wesley
    Diaz-Martinez, Juan Pablo
    Bangert, Elvira
    Ahmad, Zareen
    Soowamber, Medha
    Johnson, Sindhu
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 1303 - 1304
  • [23] Experience with azathioprine in systemic sclerosis associated with interstitial lung disease
    Dheda, K
    Lalloo, UG
    Cassim, B
    Mody, GM
    CLINICAL RHEUMATOLOGY, 2004, 23 (04) : 306 - 309
  • [24] Treatment for systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Lescoat, Alain
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2021, 33 (03) : 240 - 248
  • [25] Breathomics to monitor interstitial lung disease associated with systemic sclerosis
    Massenet, Thibault
    Potjewijd, Judith
    Tobal, Rachid
    Gester, Fanny
    Zanella, Delphine
    Henket, Monique
    Njock, Makon-Sebastien
    Dejong, Thibaut
    Gridelet, Gregory
    Giltay, Laurie
    Guissard, Francoise
    Andre, Beatrice
    Ribbens, Clio
    Louis, Renaud
    Van Paassen, Pieter
    Guiot, Julien
    Stefanuto, Pierre-Hugues
    ERJ OPEN RESEARCH, 2024, 10 (04)
  • [26] Nintedanib for systemic sclerosis-associated interstitial lung disease
    Thorley, Jennifer
    LANCET RHEUMATOLOGY, 2021, 3 (11): : E755 - E755
  • [27] Nintedanib for systemic sclerosis-associated interstitial lung disease
    Rahimi, Susan
    LANCET RESPIRATORY MEDICINE, 2020, 8 (02): : 136 - 136
  • [28] Pharmacological management of systemic sclerosis associated interstitial lung disease
    Dixon, Giles
    Adamali, Ibrahim
    Adamali, Huzaifa
    Barratt, Shaney
    Gunarwardena, Harsha
    Pauling, John D.
    EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (07) : 815 - 824
  • [29] Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease
    Moran-Mendoza, Onofre
    Alharthi, Bader
    Clements-Baker, Marie
    NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (16): : 1595 - 1595
  • [30] Management of systemic sclerosis-associated interstitial lung disease
    Roofeh, David
    Jaafar, Sara
    Vummidi, Dharshan
    Khanna, Dinesh
    CURRENT OPINION IN RHEUMATOLOGY, 2019, 31 (03) : 241 - 249